Omeros (OMER) Accumulated Expenses (2010 - 2026)
Omeros (OMER) posted Accumulated Expenses of $2.0 million for Q1 2026, down 93.33% sequentially from $29.4 million in Q4 2025, and down 80.15% YoY from $9.9 million in Q1 2025.
Omeros (OMER) Accumulated Expenses (2010 - 2026) Analysis & Trends
Omeros has reported Accumulated Expenses for 17 years, with the latest figure at $2.0 million in Q1 2026.
- Quarterly Accumulated Expenses fell 80.15% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 80.15% YoY) and the FY2025 annual result came in at $29.4 million, up 1001.91% from the prior year.
- Accumulated Expenses slipped to $2.0 million in Q1 2026 per OMER's latest filing, from $29.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $30.8 million in Q1 2023 and troughed at $300000.0 in Q4 2022.
- A 5-year average of $12.4 million and a median of $6.9 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses slumped 91.1% in 2022, then soared 1566.67% in 2023.
- Over 5 years, Accumulated Expenses stood at $300000.0 in 2022, then surged by 1566.67% to $5.0 million in 2023, then sank by 46.66% to $2.7 million in 2024, then jumped by 1001.91% to $29.4 million in 2025, then slumped by 93.33% to $2.0 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $2.0 million, $29.4 million, and $25.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.27 Mn |
| Mar 31, 2026 | 1.96 Mn |
| Dec 31, 2025 | 29.39 Mn |
| Sep 30, 2025 | 25.75 Mn |
| Jun 30, 2025 | 26.28 Mn |
| Mar 31, 2025 | 9.88 Mn |
| Dec 31, 2024 | 2.67 Mn |
| Sep 30, 2024 | 6.93 Mn |
| Jun 30, 2024 | 27.97 Mn |
| Mar 31, 2024 | 8.80 Mn |
| Dec 31, 2023 | 5.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 4.04 Mn |
| Mar 31, 2023 | 30.82 Mn |
| Dec 31, 2022 | 300,000.00 |
| Sep 30, 2022 | 18.02 Mn |
| Jun 30, 2022 | 5.17 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 500,000.00 |
| Sep 30, 2021 | 4.39 Mn |